is looking for the next breakout opportunity!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As long as the fundamentals are solid, there is no reason to sell. Although occasionally a plummeting share price for seamingly no reason can be a precursor to bad news, many times it's just the free market at work.
It's these types of opportunities that have made me consistantly profitable year-after-year.
Thanks for posting
Not at all worried and having dinner with a friend tonight who will most likely add as well after our meeting
I'm in
Huge upside potential from here!
Yeah, saw that
Will be interesting to see where he puts it next
Just put my first two trades in last week. Didn't really see anything I liked. They're CYTK and CELM if you want to check them out.
Yeah pretty crazy no? I think part of it has to do with upcoming inflation plus everyone seems to be trying really hard to convince people that the recession is over and that it's time to get back in stocks. We'll see...
Yeah, I'm still following it but sold during the last run-up... just not sure about it. They got a lot going for them and the right people involved, but I feel like they should be further ahead by now. Doesn't feel 100% right. If it goes low enough or has the right news, I'll buy back in.
I like it
Watching this one...
During Friday's trading session, China Electric Motor Inc. (NASDAQ: CELM) established a new all-time low at $4.02, sixteen cents below the previous low. The stock began trading in January of last year around $4.50 and reached a high of $9.88 in April. There appears to be no reason for the sell-off, although it could be linked to the 33.4% drop CCME experienced during the same day due to fraud allegations.
CELM is a China-based company that engages in the design, production, marketing and sale of micro motor products through its subsidiaries, Shenzhen YuePengCheng Motor Co., Ltd. and Ningbo Heng Bang Long Electrical Equipment Co., Ltd. The Company's products are incorporated into consumer electronics, automobiles, power tools, toys and household appliances.
Despite 48.90% year-over-year growth in revenues and continued profitability, CELM is now trading at a P/E of 6.1 (the average for the industry is approximately 28). The company is also undervalued by P/S, PEG, Price/Book and Price/Cash Flow. Currently two analysts cover the stock, one with a "Strong Buy" rating and one with a "Buy" rating. The average of their price targets is $9.50.
As of last report, the company had a very strong balance sheet with $75.9 million in total assets and $9.5 million in total liabilities. The management team has also shown great strength in efficiency, returning 28.1% on equity, 24.1% on assets and 28.1% on capital.
In most recent news, the company announced that through an indirect wholly owned subsidiary it will acquire Shenzhen Guofa Optoelectronics Co., Ltd. Through this acquisition, CELM will gain new production lines and expertise focused on high-end DC micro motors as well as a blue chip customer base. The acquisition is expected to be accretive immediately upon the closing.
During Friday's trading session, China Electric Motor Inc. (NASDAQ: CELM) established a new all-time low at $4.02, sixteen cents below the previous low. The stock began trading in January of last year around $4.50 and reached a high of $9.88 in April. There appears to be no reason for the sell-off, although it could be linked to the 33.4% drop CCME experienced during the same day due to fraud allegations.
CELM is a China-based company that engages in the design, production, marketing and sale of micro motor products through its subsidiaries, Shenzhen YuePengCheng Motor Co., Ltd. and Ningbo Heng Bang Long Electrical Equipment Co., Ltd. The Company's products are incorporated into consumer electronics, automobiles, power tools, toys and household appliances.
Despite 48.90% year-over-year growth in revenues and continued profitability, CELM is now trading at a P/E of 6.1 (the average for the industry is approximately 28). The company is also undervalued by P/S, PEG, Price/Book and Price/Cash Flow. Currently two analysts cover the stock, one with a "Strong Buy" rating and one with a "Buy" rating. The average of their price targets is $9.50.
As of last report, the company had a very strong balance sheet with $75.9 million in total assets and $9.5 million in total liabilities. The management team has also shown great strength in efficiency, returning 28.1% on equity, 24.1% on assets and 28.1% on capital.
In most recent news, the company announced that through an indirect wholly owned subsidiary it will acquire Shenzhen Guofa Optoelectronics Co., Ltd. Through this acquisition, CELM will gain new production lines and expertise focused on high-end DC micro motors as well as a blue chip customer base. The acquisition is expected to be accretive immediately upon the closing.
Same to you! Hoping for another great year!
Thanks! Had a wonderful Christmas this year
Hope yours was excellent as well :Thumbsup:
Haha
CRMD - One I traded recently
Really hoping it will come back down, but there's a lot of newsletters/sites getting in on this one
My DD:
CorMedix Inc. is a pharmaceutical company focused on in-licensing, developing and commercializing therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. The company's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development.
The company began trading publicly in May of this year, trading as high as $4 a share. Although the company continues to move forward and has enough cash to fund operations until April 2010 (not counting an additional $490,000 recently received from government grants), CorMedix's stock yesterday traded near its 52-week low of $1.08. The company has a market cap of $16.4 million and an enterprise value of a mere $4 million.
No drugs are currently marketed for the therapies being targeted by CorMedix. The company's Neutrolin compound could become the first FDA-approved drug that addresses one of the seven major healthcare challenges, Catheter-Related Bloodstream Infection (CRBI), as defined by the Center for Disease Control (CDC). This challenge represents an approximate $675 million per year revenue opportunity in the United States alone.
The Deferiprone compound is being developed as a therapy for Contrast Induced Nephropathy (CIN) which can lead to morbidity and death. It is already approved and available in a different formulation for sale in 50 countries outside the U.S. as a treatment for iron overload disorders. This compound addresses an approximate $365 million per year revenue opportunity.
Analysts are very supportive of the company. Two analysts have issued "Strong Buy" recommendations and another has titled the stock a "Buy". With price targets ranging from $5.00 to $13.00, the average analyst price target is $8.00. A 47 page research report is available at: http://www.lifesciadvisors.com/pdfs/Cormedix_LSA_Initiation_10-26-2010.pdf
Upcoming Expected Neutrolin (CRMD003) Milestones
• 4Q 2010: Investigational Device Exemption (IDE) application submission
• 4Q 2010: Commence Application for CE (CE means European Conformity) marketing in
Europe (EU)
• 1H 2011: Initiation of Pivotal trial for prevention of Catheter-Related Bloodstream Infection
(CRBI) in hemodialysis patients
• 2H 2011: Potential product launching in Europe
• 1H 2012: Release of preliminary data from Pivotal Phase III clinical trial
• 2H 2012: File Premarket Approval (PMA) application in the U.S
• 1H 2013: FDA approval of Neutrolin (CRMD003)
Upcoming Expected Deferiprone (CRMD001) Milestones
• 2H 2010: Deferiprone interim analysis from Phase II CIN study
• 2H 2011: Phase II data from Deferiprone study
• 2H 2011: Phase III DEFEND-AKI clinical trial (prevention of Contrast-Induced
Nephropathy in patients with Chronic Kidney Disease) – Expected to begin
• 2H 2012: Release of data from Phase III DEFEND-AKI trial
• 4Q 2012: File for New Drug Application (NDA) for Deferiprone (CRMD001)
• 2H 2013: FDA approval of Deferiprone (CRMD001)
CRMD
CorMedix Inc. is a pharmaceutical company focused on in-licensing, developing and commercializing therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. The company's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development.
The company began trading publicly in May of this year, trading as high as $4 a share. Although the company continues to move forward and has enough cash to fund operations until April 2010 (not counting an additional $490,000 recently received from government grants), CorMedix's stock yesterday traded near its 52-week low of $1.08. The company has a market cap of $16.4 million and an enterprise value of a mere $4 million.
No drugs are currently marketed for the therapies being targeted by CorMedix. The company's Neutrolin compound could become the first FDA-approved drug that addresses one of the seven major healthcare challenges, Catheter-Related Bloodstream Infection (CRBI), as defined by the Center for Disease Control (CDC). This challenge represents an approximate $675 million per year revenue opportunity in the United States alone.
The Deferiprone compound is being developed as a therapy for Contrast Induced Nephropathy (CIN) which can lead to morbidity and death. It is already approved and available in a different formulation for sale in 50 countries outside the U.S. as a treatment for iron overload disorders. This compound addresses an approximate $365 million per year revenue opportunity.
Analysts are very supportive of the company. Two analysts have issued "Strong Buy" recommendations and another has titled the stock a "Buy". With price targets ranging from $5.00 to $13.00, the average analyst price target is $8.00. A 47 page research report is available at: http://www.lifesciadvisors.com/pdfs/Cormedix_LSA_Initiation_10-26-2010.pdf
Upcoming Expected Neutrolin (CRMD003) Milestones
• 4Q 2010: Investigational Device Exemption (IDE) application submission
• 4Q 2010: Commence Application for CE (CE means European Conformity) marketing in
Europe (EU)
• 1H 2011: Initiation of Pivotal trial for prevention of Catheter-Related Bloodstream Infection
(CRBI) in hemodialysis patients
• 2H 2011: Potential product launching in Europe
• 1H 2012: Release of preliminary data from Pivotal Phase III clinical trial
• 2H 2012: File Premarket Approval (PMA) application in the U.S
• 1H 2013: FDA approval of Neutrolin (CRMD003)
Upcoming Expected Deferiprone (CRMD001) Milestones
• 2H 2010: Deferiprone interim analysis from Phase II CIN study
• 2H 2011: Phase II data from Deferiprone study
• 2H 2011: Phase III DEFEND-AKI clinical trial (prevention of Contrast-Induced
Nephropathy in patients with Chronic Kidney Disease) – Expected to begin
• 2H 2012: Release of data from Phase III DEFEND-AKI trial
• 4Q 2012: File for New Drug Application (NDA) for Deferiprone (CRMD001)
• 2H 2013: FDA approval of Deferiprone (CRMD001)
.80 spike...
Yeah, that's really nice
I'll have to keep an eye on it
+17.54%
I'm out
$2.468 Up 8.25%
News today
CAMAC Energy Announces Gas Discovery on the Zijinshan, China Asset
HOUSTON--(BUSINESS WIRE)-- CAMAC Energy Inc. (NYSE Amex:CAK), a U.S.-based energy company engaged in the exploration, development and production of oil and gas, today announced the positive results from the ZJS-02 well that was successfully drilled to a total depth of 1784 meters. Mud logs during drilling confirmed the presence of gas in several intervals ranging in depth from 1471 to 1742 meters.
The electric logs and cores obtained during the drilling are currently being evaluated by third party contractors to allow full assessment of the size of this discovery.
“We are very pleased with the progress of our work program and are now one step closer to fully appraising the commercial potential of the Zijinshan Gas Asset,” said Chief Executive Officer Byron Dunn. “The next step is to spud well ZJS-03, which will be our first well in the larger, upthrown section of the play. The Zijinshan Gas Asset is surrounded by producing fields, and we are optimistic about our prospects there.”
The Company’s Zijinshan Gas Asset covers an area of 175,000 acres in the Ordos Basin in Shanxi Province, the second largest petroleum-bearing basin in China. It is in close proximity to major infrastructure, including the West-East Gas Pipeline and the Ordos-Beijing Pipeline.
CAMAC Energy owns 100% of the foreign contract interest in the Zijinshan production sharing contract in partnership with PetroChina CBM Co.
About CAMAC Energy Inc.
CAMAC Energy Inc. (NYSE Amex: CAK) is a U.S.-based energy company engaged in the exploration, development and production of oil and gas. The Company focuses on early cash flow and high-return global energy projects and currently has operations in Nigeria and, through its Pacific Asia Petroleum subsidiaries, in China. The Company's principal assets include interests in the Oyo Oilfield, an offshore oil asset in deepwater Nigeria that started production in December 2009, a 100% interest in the Zijinshan Block gas asset located in the Shanxi Province, China, and the Enhanced Oil Recovery and Production business in Northern China. The Company was founded in 2005 and has offices in Hartsdale, New York, Houston, Texas, Beijing, China, and Lagos, Nigeria.
Forward-Looking Statements
This press release may contain certain “forward-looking statements” relating to the business of CAMAC Energy Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the general ability of CAMAC Energy Inc. to achieve its commercial objectives; the business strategy, plans and objectives of CAMAC Energy Inc. and its subsidiaries; and any other statements of non-historical information. Words such as “anticipates,” “expects,” “plans,” “projects,” “believes,” “seeks,” “estimates,” and similar expressions are intended to identify such forward-looking statements. The statements are based upon management’s current expectations, estimates and projections, are not guarantees of future performance, and are subject to a variety of risks, uncertainties and other factors, some of which are beyond CAMAC Energy Inc.’s control and are difficult to predict, including those discussed in CAMAC Energy Inc.'s periodic reports that are filed with the SEC and available on its website (http://www.sec.gov). You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, CAMAC Energy Inc. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CAK at 2.42
News today http://finance.yahoo.com/news/CAMAC-Energy-Announces-Gas-bw-1587441469.html?x=0&.v=1
And increased talk on rising oil prices
Yep, have little to complain about and a lot to be thankful for
Getting real busy again - didn't get much of a break this summer, but ready for a good slam
Good morning!
They're a company trading at $0.76 ($29M market cap) with phase II and III candidates. The biggest turn on is that they have $34.28 Million cash (including investments) and only a $29.20 Million market cap. Plus, with Thurday's announcement, the company regained full rights to Pimavanserin and $8.75 million - now they have enough to fund operations through mid-2012
For what its worth, earlier this month Valeant/BLS walked away from a North American commercialization agreement with Alexza Pharmaceuticals. Acadia may not be the cause of the termination of their agreement.
Positives from Thursday's announcment: They now have millions more in the bank, the option to re-partner for new upfront money, and the capital needed to keep funding the ongoing phase III PDP trial (which was previously funded by BLS). Acadia might also be a more attractive takeover target since they own full rights to pimavanserin.
.80 hit
After doing some research, going to hold onto this one for awhile
Just keeping busy as always :Thumbsup:
I would vote short based on the chart and recent data that came out - although the fed could change things
The rating would be bad for a company like FEEC
http://www.fixyou.co.uk/help_score.php
Rates the current condition of the company via a software bot - obviously with Far East still in the development stage, it wouldn't be able to get a high rating
Big names in this one
http://www.bloomberg.com/news/2010-09-09/blackrock-soros-fund-buy-stakes-in-far-east-energy-seeking-gas-in-china.html
Related News:China · Energy Markets · Funds .BlackRock, George Soros Fund Buy Stakes in Gas Producer Far East Energy
By David Wethe - Sep 9, 2010 10:10 PM GMT+0200
BlackRock Inc., the world’s biggest money manager, and a fund related to billionaire George Soros have acquired stakes in Far East Energy Corp., a Houston company that’s raising cash to develop natural-gas properties in China.
Far East sold new shares representing a 9.95 percent interest in the company to New York-based BlackRock for about $9.5 million, Bruce Huff, the gas producer’s chief financial officer, said today in a telephone interview. Far East sold the same size stake to a mutual fund that Huff declined to identify and an undisclosed number of shares to a Soros fund and other buyers, he said.
The sales, which were completed on Aug. 25, totaled $34.8 million. Far East is accelerating production of coalbed methane, a type of natural gas contained in coal deposits. Output in the Shouyang Block of China’s Shanxi Province surpassed 1 million cubic feet of gas a day, the company said last month. Far East has to burn off the fuel it’s producing until pipelines are in place to gather the gas later this year, Huff said.
“That’s why we’re moving so quickly to accelerate production,” he said. “The purpose here was trying to raise sufficient capital in order to really make a major impact on not only the production level, but also ultimately the potential valuation of the company.”
Far East plans to double or triple its production within four to six months, Huff said.
Melissa Garville, a spokeswoman for BlackRock, declined to comment on the investment. Michael Vachon, a spokesman for Soros, didn’t immediately respond to telephone and e-mail messages seeking comment.
Far East rose 3 cents, or 7.5 percent, to 43 cents as of 4 p.m. New York time in over-the-counter stock trading. The new shares were sold at a price of 33 cents. BlackRock fell $1.20 to $150.74.
Did nearly the exact same thing
Just got back in @ .48 partially
Will see what happens from here over the next week or so
It's definitely broken through a lot of resistance this month, leaving a lot of support underneath. But the indicators are pretty hot.
Will likely consolidate between 2.03 and 1.80 range for awhile before deciding where its going for sure.
Looks pretty good other than RSI breaking into 70 already
Wouldn't hold past $3 though unless you find reason to love the company's fundamentals